Review



galectin 9 roc curve  (Galectin Therapeutics)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Galectin Therapeutics galectin 9 roc curve
    (A) Representative flow cytometry plots showing TIM-3 expression on NK cells from healthy donors and SFTS patients. (B) Frequency of NK cells (CD3 ⁻ CD56⁺) among peripheral blood mononuclear cells (PBMCs) in healthy donors (N = 14), recovered SFTS patients (N = 17), and deceased SFTS patients (N = 4). (C) Frequency of TIM-3 ⁺ NK cells among total NK cells in the same cohorts. (D) Paired longitudinal analysis of peripheral TIM-3 + NK cell frequencies among NK cells in SFTS patients (N = 4) during the acute phase and approximately two weeks into recovery. Paired longitudinal analysis of soluble TIM-3 (E) <t>,</t> <t>Galectin-9</t> (F) , TNF-α (G) , IFN-γ (H) in plasma of SFTS patients (N = 9) during the acute and recovery phase. Each dot represents an individual donor. Box plots show the full range (min to max). Statistical analysis was performed using Kruskal–Wallis H test for (B); one-way ANOVA with Tukey’s multiple comparisons test for (C) and paired t-test for (D-H). IFN-γ, interferon gamma; NK, natural killer; sGalectin-9, soluble Galectin-9; SFTS, severe fever with thrombocytopenia syndrome; TNF-α, tumor necrosis factor alpha.
    Galectin 9 Roc Curve, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/galectin+9+roc+curve/pmc12829940-234-8-8?v=Galectin+Therapeutics
    Average 86 stars, based on 1 article reviews
    galectin 9 roc curve - by Bioz Stars, 2026-07
    86/100 stars

    Images

    1) Product Images from "Immune checkpoint TIM-3 defines hyperactivated NK cells and predicts fatal outcome in severe fever with thrombocytopenia syndrome"

    Article Title: Immune checkpoint TIM-3 defines hyperactivated NK cells and predicts fatal outcome in severe fever with thrombocytopenia syndrome

    Journal: PLOS Neglected Tropical Diseases

    doi: 10.1371/journal.pntd.0013928

    (A) Representative flow cytometry plots showing TIM-3 expression on NK cells from healthy donors and SFTS patients. (B) Frequency of NK cells (CD3 ⁻ CD56⁺) among peripheral blood mononuclear cells (PBMCs) in healthy donors (N = 14), recovered SFTS patients (N = 17), and deceased SFTS patients (N = 4). (C) Frequency of TIM-3 ⁺ NK cells among total NK cells in the same cohorts. (D) Paired longitudinal analysis of peripheral TIM-3 + NK cell frequencies among NK cells in SFTS patients (N = 4) during the acute phase and approximately two weeks into recovery. Paired longitudinal analysis of soluble TIM-3 (E) , Galectin-9 (F) , TNF-α (G) , IFN-γ (H) in plasma of SFTS patients (N = 9) during the acute and recovery phase. Each dot represents an individual donor. Box plots show the full range (min to max). Statistical analysis was performed using Kruskal–Wallis H test for (B); one-way ANOVA with Tukey’s multiple comparisons test for (C) and paired t-test for (D-H). IFN-γ, interferon gamma; NK, natural killer; sGalectin-9, soluble Galectin-9; SFTS, severe fever with thrombocytopenia syndrome; TNF-α, tumor necrosis factor alpha.
    Figure Legend Snippet: (A) Representative flow cytometry plots showing TIM-3 expression on NK cells from healthy donors and SFTS patients. (B) Frequency of NK cells (CD3 ⁻ CD56⁺) among peripheral blood mononuclear cells (PBMCs) in healthy donors (N = 14), recovered SFTS patients (N = 17), and deceased SFTS patients (N = 4). (C) Frequency of TIM-3 ⁺ NK cells among total NK cells in the same cohorts. (D) Paired longitudinal analysis of peripheral TIM-3 + NK cell frequencies among NK cells in SFTS patients (N = 4) during the acute phase and approximately two weeks into recovery. Paired longitudinal analysis of soluble TIM-3 (E) , Galectin-9 (F) , TNF-α (G) , IFN-γ (H) in plasma of SFTS patients (N = 9) during the acute and recovery phase. Each dot represents an individual donor. Box plots show the full range (min to max). Statistical analysis was performed using Kruskal–Wallis H test for (B); one-way ANOVA with Tukey’s multiple comparisons test for (C) and paired t-test for (D-H). IFN-γ, interferon gamma; NK, natural killer; sGalectin-9, soluble Galectin-9; SFTS, severe fever with thrombocytopenia syndrome; TNF-α, tumor necrosis factor alpha.

    Techniques Used: Flow Cytometry, Expressing, Clinical Proteomics

    (A) Serum levels of soluble TIM-3 (sTIM-3) and Galectin-9 in healthy individuals (N = 10), recovered SFTS patients (N = 17), and deceased SFTS patients (N = 4). (B) Pearson correlation analysis between sTIM-3 levels, Galectin-9 levels, and the frequency of TIM-3 + NK cells among NK cells with clinical characteristics. (C) ROC curves of serum Galectin-9, sTIM-3, and the frequency of TIM-3 ⁺ NK cells in predicting fatal outcome in the same cohort. (D) ROC curves of serum Galectin-9 and sTIM-3 in the validation cohort (N = 104), with AUC, sensitivity, and specificity calculated using the Youden index. (E) Kaplan–Meier survival analysis stratified by high vs. low serum Galectin-9 levels in the validation cohort (N = 104), using the ROC-derived optimal cutoff. Statistical significance was assessed using the Mann-Whitney test for (A), and Pearson correlation analysis with the Benjamini-Hochberg correction for (B), DeLong’s test for (C-D) and the log-rank test for (E). sTIM-3, soluble T cell immunoglobulin and mucin domain-3; Gal-9, galectin-9; CCI, Charlson comorbidity index; PLT, platelet count; AST, aspartate aminotransferase; Cr, creatinine; ROC, receiver operating characteristic curve; AUC, area under the ROC curve.
    Figure Legend Snippet: (A) Serum levels of soluble TIM-3 (sTIM-3) and Galectin-9 in healthy individuals (N = 10), recovered SFTS patients (N = 17), and deceased SFTS patients (N = 4). (B) Pearson correlation analysis between sTIM-3 levels, Galectin-9 levels, and the frequency of TIM-3 + NK cells among NK cells with clinical characteristics. (C) ROC curves of serum Galectin-9, sTIM-3, and the frequency of TIM-3 ⁺ NK cells in predicting fatal outcome in the same cohort. (D) ROC curves of serum Galectin-9 and sTIM-3 in the validation cohort (N = 104), with AUC, sensitivity, and specificity calculated using the Youden index. (E) Kaplan–Meier survival analysis stratified by high vs. low serum Galectin-9 levels in the validation cohort (N = 104), using the ROC-derived optimal cutoff. Statistical significance was assessed using the Mann-Whitney test for (A), and Pearson correlation analysis with the Benjamini-Hochberg correction for (B), DeLong’s test for (C-D) and the log-rank test for (E). sTIM-3, soluble T cell immunoglobulin and mucin domain-3; Gal-9, galectin-9; CCI, Charlson comorbidity index; PLT, platelet count; AST, aspartate aminotransferase; Cr, creatinine; ROC, receiver operating characteristic curve; AUC, area under the ROC curve.

    Techniques Used: Biomarker Discovery, Derivative Assay, MANN-WHITNEY



    Similar Products

    galectin 9 roc curve  (Galectin Therapeutics)
    86
    Galectin Therapeutics galectin 9 roc curve
    (A) Representative flow cytometry plots showing TIM-3 expression on NK cells from healthy donors and SFTS patients. (B) Frequency of NK cells (CD3 ⁻ CD56⁺) among peripheral blood mononuclear cells (PBMCs) in healthy donors (N = 14), recovered SFTS patients (N = 17), and deceased SFTS patients (N = 4). (C) Frequency of TIM-3 ⁺ NK cells among total NK cells in the same cohorts. (D) Paired longitudinal analysis of peripheral TIM-3 + NK cell frequencies among NK cells in SFTS patients (N = 4) during the acute phase and approximately two weeks into recovery. Paired longitudinal analysis of soluble TIM-3 (E) <t>,</t> <t>Galectin-9</t> (F) , TNF-α (G) , IFN-γ (H) in plasma of SFTS patients (N = 9) during the acute and recovery phase. Each dot represents an individual donor. Box plots show the full range (min to max). Statistical analysis was performed using Kruskal–Wallis H test for (B); one-way ANOVA with Tukey’s multiple comparisons test for (C) and paired t-test for (D-H). IFN-γ, interferon gamma; NK, natural killer; sGalectin-9, soluble Galectin-9; SFTS, severe fever with thrombocytopenia syndrome; TNF-α, tumor necrosis factor alpha.
    Galectin 9 Roc Curve, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/galectin+9+roc+curve/pmc12829940-234-8-8?v=Galectin+Therapeutics
    Average 86 stars, based on 1 article reviews
    galectin 9 roc curve - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Representative flow cytometry plots showing TIM-3 expression on NK cells from healthy donors and SFTS patients. (B) Frequency of NK cells (CD3 ⁻ CD56⁺) among peripheral blood mononuclear cells (PBMCs) in healthy donors (N = 14), recovered SFTS patients (N = 17), and deceased SFTS patients (N = 4). (C) Frequency of TIM-3 ⁺ NK cells among total NK cells in the same cohorts. (D) Paired longitudinal analysis of peripheral TIM-3 + NK cell frequencies among NK cells in SFTS patients (N = 4) during the acute phase and approximately two weeks into recovery. Paired longitudinal analysis of soluble TIM-3 (E) , Galectin-9 (F) , TNF-α (G) , IFN-γ (H) in plasma of SFTS patients (N = 9) during the acute and recovery phase. Each dot represents an individual donor. Box plots show the full range (min to max). Statistical analysis was performed using Kruskal–Wallis H test for (B); one-way ANOVA with Tukey’s multiple comparisons test for (C) and paired t-test for (D-H). IFN-γ, interferon gamma; NK, natural killer; sGalectin-9, soluble Galectin-9; SFTS, severe fever with thrombocytopenia syndrome; TNF-α, tumor necrosis factor alpha.

    Journal: PLOS Neglected Tropical Diseases

    Article Title: Immune checkpoint TIM-3 defines hyperactivated NK cells and predicts fatal outcome in severe fever with thrombocytopenia syndrome

    doi: 10.1371/journal.pntd.0013928

    Figure Lengend Snippet: (A) Representative flow cytometry plots showing TIM-3 expression on NK cells from healthy donors and SFTS patients. (B) Frequency of NK cells (CD3 ⁻ CD56⁺) among peripheral blood mononuclear cells (PBMCs) in healthy donors (N = 14), recovered SFTS patients (N = 17), and deceased SFTS patients (N = 4). (C) Frequency of TIM-3 ⁺ NK cells among total NK cells in the same cohorts. (D) Paired longitudinal analysis of peripheral TIM-3 + NK cell frequencies among NK cells in SFTS patients (N = 4) during the acute phase and approximately two weeks into recovery. Paired longitudinal analysis of soluble TIM-3 (E) , Galectin-9 (F) , TNF-α (G) , IFN-γ (H) in plasma of SFTS patients (N = 9) during the acute and recovery phase. Each dot represents an individual donor. Box plots show the full range (min to max). Statistical analysis was performed using Kruskal–Wallis H test for (B); one-way ANOVA with Tukey’s multiple comparisons test for (C) and paired t-test for (D-H). IFN-γ, interferon gamma; NK, natural killer; sGalectin-9, soluble Galectin-9; SFTS, severe fever with thrombocytopenia syndrome; TNF-α, tumor necrosis factor alpha.

    Article Snippet: Based on the optimal cutoff derived from the Galectin-9 ROC curve, patients were stratified into high- and low-expression groups.

    Techniques: Flow Cytometry, Expressing, Clinical Proteomics

    (A) Serum levels of soluble TIM-3 (sTIM-3) and Galectin-9 in healthy individuals (N = 10), recovered SFTS patients (N = 17), and deceased SFTS patients (N = 4). (B) Pearson correlation analysis between sTIM-3 levels, Galectin-9 levels, and the frequency of TIM-3 + NK cells among NK cells with clinical characteristics. (C) ROC curves of serum Galectin-9, sTIM-3, and the frequency of TIM-3 ⁺ NK cells in predicting fatal outcome in the same cohort. (D) ROC curves of serum Galectin-9 and sTIM-3 in the validation cohort (N = 104), with AUC, sensitivity, and specificity calculated using the Youden index. (E) Kaplan–Meier survival analysis stratified by high vs. low serum Galectin-9 levels in the validation cohort (N = 104), using the ROC-derived optimal cutoff. Statistical significance was assessed using the Mann-Whitney test for (A), and Pearson correlation analysis with the Benjamini-Hochberg correction for (B), DeLong’s test for (C-D) and the log-rank test for (E). sTIM-3, soluble T cell immunoglobulin and mucin domain-3; Gal-9, galectin-9; CCI, Charlson comorbidity index; PLT, platelet count; AST, aspartate aminotransferase; Cr, creatinine; ROC, receiver operating characteristic curve; AUC, area under the ROC curve.

    Journal: PLOS Neglected Tropical Diseases

    Article Title: Immune checkpoint TIM-3 defines hyperactivated NK cells and predicts fatal outcome in severe fever with thrombocytopenia syndrome

    doi: 10.1371/journal.pntd.0013928

    Figure Lengend Snippet: (A) Serum levels of soluble TIM-3 (sTIM-3) and Galectin-9 in healthy individuals (N = 10), recovered SFTS patients (N = 17), and deceased SFTS patients (N = 4). (B) Pearson correlation analysis between sTIM-3 levels, Galectin-9 levels, and the frequency of TIM-3 + NK cells among NK cells with clinical characteristics. (C) ROC curves of serum Galectin-9, sTIM-3, and the frequency of TIM-3 ⁺ NK cells in predicting fatal outcome in the same cohort. (D) ROC curves of serum Galectin-9 and sTIM-3 in the validation cohort (N = 104), with AUC, sensitivity, and specificity calculated using the Youden index. (E) Kaplan–Meier survival analysis stratified by high vs. low serum Galectin-9 levels in the validation cohort (N = 104), using the ROC-derived optimal cutoff. Statistical significance was assessed using the Mann-Whitney test for (A), and Pearson correlation analysis with the Benjamini-Hochberg correction for (B), DeLong’s test for (C-D) and the log-rank test for (E). sTIM-3, soluble T cell immunoglobulin and mucin domain-3; Gal-9, galectin-9; CCI, Charlson comorbidity index; PLT, platelet count; AST, aspartate aminotransferase; Cr, creatinine; ROC, receiver operating characteristic curve; AUC, area under the ROC curve.

    Article Snippet: Based on the optimal cutoff derived from the Galectin-9 ROC curve, patients were stratified into high- and low-expression groups.

    Techniques: Biomarker Discovery, Derivative Assay, MANN-WHITNEY